Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
